keyword
MENU ▼
Read by QxMD icon Read
search

Crohn´s disease

keyword
https://www.readbyqxmd.com/read/29901557/association-between-infliximab-drug-and-antibody-levels-and-therapy-outcome-in-pediatric-inflammatory-bowel-diseases
#1
Bella Ungar, Yoav Glidai, Miri Yavzori, Orit Picard, Ella Fudim, Avishay Lahad, Yael Haberman, Dror S Shouval, Ilana Weintraub, Rami Eliakim, Shomron Ben-Horin, Batia Weiss
OBJECTIVES: While infliximab pharmacokinetics are associated with therapy outcome in adult IBD population, limited data is available in pediatric patients. We aimed to define the relationship between Infliximab trough and antibodies' levels (IFX-TL, ATI) and clinical, biomarker remission. METHODS: IFX-TL and ATI were routinely obtained between 2011-2017. Associations with clinical and inflammatory (C-reactive protein, CRP) end-points were studied throughout the first year of infliximab therapy...
June 12, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29890635/a-neglected-issue-in-ulcerative-colitis-mesenteric-lymph-nodes
#2
Abdurrahman Sahin, Hakan Artas, Yesim Eroglu, Nurettin Tunc, Gulcan Oguz, Ulvi Demirel, Orhan Kursat Poyrazoglu, Mehmet Yalniz, Ibrahim Halil Bahcecioglu
Data evaluating the presence and characteristics of mesenteric lymph nodes (LNs) in patients with ulcerative colitis (UC) are scarce. The aim of this study is to determine the presence and characteristics of LNs in UC. The LN characteristics in computed tomography (CT), including LN dimension and attenuation, were evaluated retrospectively in 100 patients with UC (61 active and 39 inactive cases). Clinical characteristics and laboratory parameters, including CBC, biochemical analysis, erythrocyte sedimentation rate (ESR), and C reactive protein (CRP) were also compared...
June 8, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29884528/-miescher-s-granulomatous-vulvitis
#3
K Alhazmi, S Berville, M Moyal-Barracco, F Plantier
BACKGROUND: Miescher's cheilitis, whether occurring alone or as part of Melkersson-Rosenthal syndrome, is a rare type of granulomatous inflammation of unknown cause with an even rarer genital equivalent. Herein, we describe a case of the latter condition developing over a 12-year period. PATIENTS AND METHODS: A 27-year-old woman presented episodes of unilateral vulvar oedema, which initially regressed but resulted over time in permanent vulvar and perineal tumefaction...
June 5, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29876356/asians-have-more-perianal-crohn-disease-and-ocular-manifestations-compared-with-white-americans
#4
Bharati Kochar, Edward L Barnes, Hans H Herfarth, Christopher F Martin, Ashwin N Ananthakrishnan, Dermot McGovern, Millie Long, Robert S Sandler
Background: Inflammatory bowel disease (IBD) is increasing in Asians. We sought tobetter understand differences in IBD between Asians and whites in the United States (U.S.). Methods: We used data from the Sinai-Helmsley Alliance for Research Excellence cohort to assess disease characteristics for U.S.-born Asians, Asian immigrants and whites. We used bivariate analyses to describe clinical characteristics by race. We used logistic regression to determine baseline odds of immunosuppression and binomial regression to estimate risk ratios for worsening disease at follow-up...
March 2018: Inflammatory Intestinal Diseases
https://www.readbyqxmd.com/read/29872891/-inflammatory-bowel-diseases-crohn-s-disease-and-ulcerative-colitis
#5
S Fischer, T Rath, M F Neurath
Inflammatory bowel diseases (IBD) are complex diseases. Epidemiological studies suggest rising incidences in industrialized countries. The article is based on a literature search in PubMed and is oriented on the current guidelines published by the European Crohn's and Colitis Organisation. IBD are characterized by chronic diarrhoea, abdominal pain and peranal haemorrhage. Extraintestinal manifestations commonly affect joints, skin, eyes and bile tracts. Early diagnosis and therapeutic intervention determine individual patient outcome...
June 5, 2018: Der Internist
https://www.readbyqxmd.com/read/29869804/incidence-of-psoriasiform-diseases-secondary-to-tumour-necrosis-factor-antagonists-in-patients-with-inflammatory-bowel-disease-a-nationwide-population-based-cohort-study
#6
J M Bae, H H Lee, B-I Lee, K-M Lee, S H Eun, M-L Cho, J S Kim, J M Park, Y-S Cho, I S Lee, S W Kim, H Choi, M-G Choi
BACKGROUND: There are increasing reports of paradoxical psoriasiform diseases secondary to anti-tumour necrosis factor (TNF) agents. AIMS: To determine the risks of paradoxical psoriasiform diseases secondary to anti-TNF agents in patients with inflammatory bowel disease (IBD). METHODS: A nationwide population study was performed using the Korea National Health Insurance Claim Data. A total of 50 502 patients with IBD were identified between 2007 and 2016...
June 5, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29860529/evolution-of-pediatric-inflammatory-bowel-disease-unclassified-ibd-u-incorporated-with-serological-and-gene-expression-profiles
#7
Raguraj Chandradevan, Tatyana Hofmekler, Kajari Mondal, Nusrat Harun, Suresh Venkateswaran, Hari K Somineni, Cortney R Ballengee, Mi-Ok Kim, Anne Griffiths, Joshua D Noe, Wallace V Crandall, Scott Snapper, Shervin Rabizadeh, Joel R Rosh, Thomas D Walters, Madeline Bertha, Marla C Dubinsky, Lee A Denson, Cary G Sauer, James F Markowitz, Neal S LeLeiko, Jeffrey S Hyams, Subra Kugathasan
Background: Inflammatory bowel disease (IBD) mainly consists of Crohn's disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel disease unclassified (IBD-U). Having a firm diagnosis is clearly preferred to guide treatment choices, and better understanding of the nature of IBD-U is required. Methods: We performed an analysis of a subset of pediatric subjects from an inception IBD cohort of patients initially enrolled in a prospective multicenter study (the RISK study)...
May 30, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29851091/systematic-review-and-meta-analysis-prevalence-risk-factors-and-costs-of-aminosalicylate-use-in-crohn-s-disease
#8
REVIEW
C Ma, S J Dutton, L E Cipriano, S Singh, C E Parker, T M Nguyen, L Guizzetti, J C Gregor, N Chande, P Hindryckx, B G Feagan, V Jairath
BACKGROUND: Aminosalicylates are the most frequently prescribed drugs for patients with Crohn's disease (CD), yet evidence to support their efficacy as induction or maintenance therapy is controversial. AIMS: To quantify aminosalicylate use in CD clinical trials, identify factors associated with use and estimate direct annual treatment costs of therapy. METHODS: MEDLINE, Embase and CENTRAL were searched to April 2017 for placebo-controlled trials in adults with CD treated with corticosteroids, immunosuppressants or biologics...
May 30, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29846530/a-phase-2-randomized-placebo-controlled-study-evaluating-matrix-metalloproteinase-9-inhibitor-andecaliximab-in-patients-with-moderately-to-severely-active-crohn-s-disease
#9
Stefan Schreiber, Corey A Siegel, Keith A Friedenberg, Ziad H Younes, Ursula Seidler, Bal R Bhandari, Ke Wang, Emily Wendt, Matt McKevitt, Sally Zhao, John S Sundy, Scott D Lee, Edward V Loftus
Background and Aims: Matrix metalloproteinase-9 (MMP9) is implicated in the pathogenesis of Crohn's disease and may serve as a potential biomarker. A phase 2 trial was conducted to examine the efficacy and safety of the anti-MMP9 antibody, andecaliximab (GS-5745), in patients with moderately to severely active Crohn's disease. Methods: Patients were randomized 1:2:2:2 to receive subcutaneous injections of placebo weekly (QW), andecaliximab 150 mg every 2 weeks (Q2W), andecaliximab 150 mg QW, or andecaliximab 300 mg QW...
May 29, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29843908/malnutrition-increases-the-risk-of-30-day-complications-after-surgery-in-pediatric-patients-with-crohn-disease
#10
Mitchell R Ladd, Alejandro V Garcia, Ira L Leeds, Courtney Haney, Maria M Oliva-Hemker, Samuel Alaish, Emily Boss, Daniel S Rhee
BACKGROUND: Pediatric patients with Crohn disease (CD) are frequently malnourished, yet how this affects surgical outcomes has not been evaluated. This study aims to determine the effects of malnourishment in children with CD on 30-day outcomes after surgery. STUDY DESIGN: The ACS NSQIP-Pediatric database from 2012 to 2015 was used to select children aged 5-18 with CD who underwent bowel surgery. BMI-for-age Z-scores were calculated based on CDC growth charts and 2015 guidelines of pediatric malnutrition were applied to categorize severity of malnutrition into none, mild, moderate, or severe...
April 27, 2018: Journal of Pediatric Surgery
https://www.readbyqxmd.com/read/29843853/differentiating-crohn-s-disease-from-intestinal-tuberculosis-at-presentation-in-patients-with-tissue-granulomas
#11
G Watermeyer, S Thomson
BACKGROUND: Overlapping clinical, endoscopic, radiographic and histological features, coupled with poor microbiological yield, make differentiating Crohn's disease (CD) from intestinal tuberculosis (ITB) challenging. Granulomas are present in both diseases; in CD they predict the need for immunosuppressive therapy that requires ITB to be excluded before initiation. OBJECTIVES: To compare granuloma-positive CD and ITB, to identify factors that may aid in diagnosis...
April 25, 2018: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/29808485/effects-of-vedolizumab-adalimumab-and-infliximab-on-biliary-inflammation-in-individuals-with-primary-sclerosing-cholangitis-and-inflammatory-bowel-disease
#12
C S Tse, E V Loftus, L E Raffals, A A Gossard, A L Lightner
BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure. AIM: To evaluate the effect of biological therapies on PSC progression in IBD patients. METHODS: We performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017...
May 28, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29801597/volatile-metabolites-in-breath-strongly-correlate-with-gut-microbiome-in-cd-patients
#13
Agnieszka Smolinska, Danyta I Tedjo, Lionel Blanchet, Alexander Bodelier, Marieke J Pierik, Ad A M Masclee, Jan Dallinga, Paul H M Savelkoul, Daisy M A E Jonkers, John Penders, Frederik-Jan van Schooten
Microbiota composition and its metabolic capacity are very important for host health. Evidence suggests that gut microbiome is involved in the metabolites production by host-microbiome interaction. These metabolites can be absorbed in blood and excreted in exhaled air. Although, profiles of gut microbiota and exhaled metabolites were associated with gastrointestinal diseases, a direct link between them has not yet been investigated. The aim of the study was to investigate the relation between volatiles in breath and gut microbiome in active and quiescent Crohn's disease (CD) via a multivariate statistical approach...
September 26, 2018: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29797519/long-term-efficacy-and-safety-of-ustekinumab-for-crohn-s-disease-through-the-second-year-of-therapy
#14
W J Sandborn, P Rutgeerts, C Gasink, D Jacobstein, B Zou, J Johanns, B E Sands, S B Hanauer, S Targan, S Ghosh, W J S de Villiers, J-F Colombel, B G Feagan
BACKGROUND: In Phase 3 studies of ustekinumab, a fully human monoclonal IL-12/23p40 antibody approved for moderate-to-severe Crohn's disease, patients entered a long-term extension after completing 8 weeks of induction and 44 weeks of maintenance treatment. Efficacy through 92 weeks and safety through 96 weeks of IM-UNITI maintenance are reported. METHODS: UNITI-1 (TNF-antagonist failures) and UNITI-2 (conventional therapy failures) patients (N = 1281) entered IM-UNITI, including 397 ustekinumab intravenous induction responders randomised to subcutaneous ustekinumab 90 mg every 12 weeks, every 8 weeks, or placebo and 884 nonrandomised patients...
May 24, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29795570/insights-into-the-genetic-epidemiology-of-crohn-s-and-rare-diseases-in-the-ashkenazi-jewish-population
#15
Manuel A Rivas, Brandon E Avila, Jukka Koskela, Hailiang Huang, Christine Stevens, Matti Pirinen, Talin Haritunians, Benjamin M Neale, Mitja Kurki, Andrea Ganna, Daniel Graham, Benjamin Glaser, Inga Peter, Gil Atzmon, Nir Barzilai, Adam P Levine, Elena Schiff, Nikolas Pontikos, Ben Weisburd, Monkol Lek, Konrad J Karczewski, Jonathan Bloom, Eric V Minikel, Britt-Sabina Petersen, Laurent Beaugerie, Philippe Seksik, Jacques Cosnes, Stefan Schreiber, Bernd Bokemeyer, Johannes Bethge, Graham Heap, Tariq Ahmad, Vincent Plagnol, Anthony W Segal, Stephan Targan, Dan Turner, Paivi Saavalainen, Martti Farkkila, Kimmo Kontula, Aarno Palotie, Steven R Brant, Richard H Duerr, Mark S Silverberg, John D Rioux, Rinse K Weersma, Andre Franke, Luke Jostins, Carl A Anderson, Jeffrey C Barrett, Daniel G MacArthur, Chaim Jalas, Harry Sokol, Ramnik J Xavier, Ann Pulver, Judy H Cho, Dermot P B McGovern, Mark J Daly
As part of a broader collaborative network of exome sequencing studies, we developed a jointly called data set of 5,685 Ashkenazi Jewish exomes. We make publicly available a resource of site and allele frequencies, which should serve as a reference for medical genetics in the Ashkenazim (hosted in part at https://ibd.broadinstitute.org, also available in gnomAD at http://gnomad.broadinstitute.org). We estimate that 34% of protein-coding alleles present in the Ashkenazi Jewish population at frequencies greater than 0...
May 2018: PLoS Genetics
https://www.readbyqxmd.com/read/29794876/prevalence-and-associations-of-avascular-necrosis-of-the-hip-in-a-large-well-characterized-cohort-of-patients-with-inflammatory-bowel-disease
#16
Vineet S Rolston, Anish V Patel, Thomas J Learch, Dalin Li, Dmitry Karayev, Chadwick Williams, Madhavi L Siddanthi, Stephan R Targan, Michael H Weisman, Dermot P B McGovern
OBJECTIVES: Avascular necrosis (AVN) is associated with significant morbidity potentially causing severe pain and debility; patients with inflammatory bowel disease (IBD) have a higher prevalence of AVN compared with non-IBD populations. The purpose of our study was to determine the prevalence of AVN in our IBD population and to evaluate these subjects for the presence of clinical characteristics associated with AVN on computed tomography (CT) imaging. METHODS: In 1313 IBD patients with abdomen/pelvis CT scans, we identified 27 patients (2...
May 24, 2018: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29792883/plasma-n-glycan-signatures-associate-with-features-of-inflammatory-bowel-diseases
#17
Florent Clerc, Mislav Novokmet, Viktoria Dotz, Karli R Reiding, Noortje de Haan, Guinevere S M Kammeijer, Hans Dalebout, Marco R Bladergroen, Frano Vukovic, Erdmann Rapp, Stephan R Targan, Gildardo Barron, Natalia Manetti, Anna Latiano, Dermot P B McGovern, Vito Annese, Gordan Lauc, Manfred Wuhrer
BACKGROUND & AIMS: Biomarkers are needed for early detection of Crohn's disease (CD) and ulcerative colitis (UC) or to predict patient outcomes. Glycosylation is a common and complex post-translational modification of proteins that affects their structure and activity. We compared plasma N-glycosylation profiles between patients with CD or UC and healthy individuals (controls). METHODS: We analyzed the total plasma N-glycomes of 2635 patients with inflammatory bowel diseases and 996 controls by mass spectrometry with a linkage-specific sialic acid derivatization technique...
May 21, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29791168/impact-of-surgery-on-quality-of-life-in-crohn%C3%A2-s-disease-patients-final-results-of-czech-cohort
#18
Lumír Kunovský, Ladislav Mitas, Filip Marek, Jiri Dolina, Karolina Poredska, Lenka Kucerova, Klara Benesova, Zdeněk Kala
INTRODUCTION: Crohns disease (CD) belongs to chronic diseases that highly affect the patient´s quality of life (QoL). The effect of the disease and impairment of QoL in CD patients is already known. The aim was to assess how surgical treatment influences the patients QoL and determine factors that can affect postoperative QoL. METHODS AND PATIENTS: We compared the QoL before and after surgery in patients who had undergone a bowel resection at our department due to CD between 2010-2016...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29789682/the-role-of-diet-in-the-aetiopathogenesis-of-inflammatory-bowel-disease
#19
REVIEW
Hamed Khalili, Simon S M Chan, Paul Lochhead, Ashwin N Ananthakrishnan, Andrew R Hart, Andrew T Chan
Crohn's disease and ulcerative colitis, collectively known as IBD, are chronic inflammatory disorders of the gastrointestinal tract. Although the aetiopathogenesis of IBD is largely unknown, it is widely thought that diet has a crucial role in the development and progression of IBD. Indeed, epidemiological and genetic association studies have identified a number of promising dietary and genetic risk factors for IBD. These preliminary studies have led to major interest in investigating the complex interaction between diet, host genetics, the gut microbiota and immune function in the pathogenesis of IBD...
May 22, 2018: Nature Reviews. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29788240/predictors-and-management-of-loss-of-response-to-vedolizumab-in-inflammatory-bowel-disease
#20
Eugenia Shmidt, Gursimran Kochhar, Justin Hartke, Prianka Chilukuri, Joseph Meserve, Khadija Chaudrey, Jenna L Koliani-Pace, Robert Hirten, David Faleck, Morris Barocas, Michelle Luo, Karen Lasch, Brigid S Boland, Siddharth Singh, Niels Vande Casteele, Sashidhar Varma Sagi, Monika Fischer, Shannon Chang, Matthew Bohm, Dana Lukin, Keith Sultan, Arun Swaminath, David Hudesman, Nitin Gupta, Sunanda Kane, Edward V Loftus, William J Sandborn, Corey A Siegel, Bruce E Sands, Jean-Frederic Colombel, Bo Shen, Parambir S Dulai
Background: We quantified loss of response (LOR) to vedolizumab (VDZ) in clinical practice and assessed the effectiveness of VDZ dose intensification for managing LOR. Methods: Retrospective review (May 2014-December 2016) of a prospectively maintained inflammatory bowel disease (IBD) registry. Kaplan-Meier estimates were used to determine rates of LOR to VDZ . Independent predictors of LOR were identified using univariate and multivariable Cox proportional hazard regression...
May 18, 2018: Inflammatory Bowel Diseases
keyword
keyword
115575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"